These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21254375)

  • 1. Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors.
    Corrias MV; Haupt R; Carlini B; Cappelli E; Giardino S; Tripodi G; Tonini GP; Garaventa A; Pistoia V; Pistorio A
    Pediatr Blood Cancer; 2012 Jan; 58(1):43-9. PubMed ID: 21254375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells.
    Hartomo TB; Kozaki A; Hasegawa D; Van Huyen Pham T; Yamamoto N; Saitoh A; Ishida T; Kawasaki K; Kosaka Y; Ohashi H; Yamamoto T; Morikawa S; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Iijima K; Matsuo M; Nishio H; Nishimura N
    Oncol Rep; 2013 Apr; 29(4):1629-36. PubMed ID: 23417100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
    Cheung IY; Sahota A; Cheung NK
    Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
    Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
    Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
    Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of neuroblastoma cells during clinical follow up: advanced flow cytometry and rt-PCR for tyrosine hydroxylase using both conventional and real-time PCR.
    Esser R; Glienke W; Bochennek K; Erben S; Quaiser A; Pieper C; Eggert A; Schramm A; Astrahantseff K; Hansmann ML; Schwabe D; Klingebiel T; Koehl U
    Klin Padiatr; 2011 Nov; 223(6):326-31. PubMed ID: 22095188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma.
    Cheung IY; Cheung NK
    Clin Cancer Res; 1997 May; 3(5):821-6. PubMed ID: 9815755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.
    Stutterheim J; Zappeij-Kannegieter L; Ora I; van Sluis PG; Bras J; den Ouden E; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    J Mol Diagn; 2012; 14(2):168-75. PubMed ID: 22251610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The TH, ELAVL4 and GD2 gene expression as diagnostic markers of bone marrow lesions in patients with neuroblastoma].
    Druĭ AE; Tsaur GA; Popov AM; Tuponogov SN; Shorikov EV; Tsvirenko SV; Savel'ev LI; Fechina LG
    Vopr Onkol; 2012; 58(4):514-20. PubMed ID: 23607207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers.
    Cheung IY; Barber D; Cheung NK
    Clin Cancer Res; 1998 Nov; 4(11):2801-5. PubMed ID: 9829745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma.
    Stutterheim J; Zappeij-Kannegieter L; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    Eur J Cancer; 2011 May; 47(8):1193-202. PubMed ID: 21429738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of the detection of microcirculating tumor cells by a real-time RT-PCR assay of tyrosine hydroxylase in patients with advanced neuroblastoma.
    Parareda A; Gallego S; Roma J; Llort A; Sábado C; Gros L; De Toledo JS
    Oncol Rep; 2005 Oct; 14(4):1021-7. PubMed ID: 16142367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer.
    Chen LC; Brown AB; Cheung IY; Cheung NK; Kris MG; Krug LM
    Lung Cancer; 2010 Feb; 67(2):216-20. PubMed ID: 19457569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration.
    Cai JY; Pan C; Tang YJ; Chen J; Ye QD; Zhou M; Xue H; Tang JY
    Am J Clin Oncol; 2012 Jun; 35(3):275-8. PubMed ID: 21537148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
    Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
    Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
    Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
    Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma.
    Shono K; Tajiri T; Fujii Y; Suita S
    J Pediatr Surg; 2000 Oct; 35(10):1415-20. PubMed ID: 11051140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.
    Cheung IY; Cheung NK
    Clin Cancer Res; 2001 Jun; 7(6):1698-705. PubMed ID: 11410509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.
    Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Yalcin B; Dee R; van Noesel MM; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    Clin Chem; 2009 Jul; 55(7):1316-26. PubMed ID: 19460840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.